Search | Clinical Trials Finder

Conditions: Insomnia, Alcohol Use, Marijuana Use
Interventions: Brief Behavioral Therapy for Insomnia (BBTI), Brief Alcohol Screening and Intervention for College Students (BASICS), Attention Control; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 29 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Overweight, Hypertension, Diabetes Mellitus
Interventions: MOVE OUT, MOVE!; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 3,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pelvic Organ Prolapse
Interventions: VCE, Survey; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Radiation Therapy, Metastatic Cancer
Interventions: Questionnaires, Early Radiation Oncology Involvement Alongside Standard Oncologic Care; Other · Combination Product
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Jersey City, New Jersey • New Brunswick, New Jersey • Newark, New Jersey + 1 more

Conditions: Heart Failure
Interventions: Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking; Drug · Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more

Conditions: Health Care, Pediatrics, Transitional Care, Comparative Effectiveness, Family Engagement
Interventions: Focused Dose Hospital-to-Home Transitional Care Interventions, Extended Dose Hospital-to-Home Transitional Care Interventions; Behavioral
Lead sponsor: Duke University; Other
Eligibility: Up to 18 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Jaw, Edentulous, Partially
Interventions: PrimeTaper EV implant; Device
Lead sponsor: Dentsply Sirona Implants and Consumables; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: Chest Radiography, Computed Tomography, Follow-Up, Imaging Technique, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung; Node
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hospital Readmission
Interventions: CHS Transition Services; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Acneiform Drug Eruption, Acneiform Eruptions
Interventions: Isotretinoin, Doxycycline, Blood specimen collection, Photographs of Rash, Questionnaires, Stool Specimen collection; Drug · Procedure · Other + 1 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 39 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dementia, Psychiatric Disorders Mood, Behavior Disorders
Interventions: Delayed results of pharmacogenomic results; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Headache, Traumatic Brain Injury
Interventions: Traditional Chinese Acupuncture (TCA), Auricular (Ear) Acupuncture, Usual Care; Procedure · Other
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia

Conditions: Asthma
Interventions: Emergency Department based asthma follow-up clinic; Behavioral
Lead sponsor: Stephen J. Teach, MD, MPH; Other
Eligibility: 12 Months to 17 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Colorectal Carcinoma
Interventions: Best Practice, Communication Intervention, Coordination, Educational Intervention, Electronic Health Record Review, Informational Intervention, Interview, Patient Navigation, Referral, Text Message-Based Navigation Intervention; Other · Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Interventions: Biological sample collection, Data Collection: Clinical Care Assessments; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Alzheimer Disease and Related Dementias
Interventions: Dementia Care Management Checklist for Hospice Transitions; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Arthroplasty
Interventions: Baseline Questionnaire, Operative Data, Intra-operative data will be collected post-operatively, In-hospital post-operative data will be collected, Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires, Cost Data, Follow-up questionnaires; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Fracture, Fracture Nonunion, Fractures, Bone, Vitamin D
Interventions: Vitamin D Assessment, Fracture; Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Concussion, Brain, Sleep Disorder
Interventions: Brief Sleep Intervention; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Neoplasms
Interventions: MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more

Conditions: Temporomandibular Joint and Muscle Disorder
Interventions: Biobehavioral, Active Coping/Attention Intervention; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Traumatic Brain Injury
Interventions: BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery), Usual Care; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)

MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA)

Postoperative Virtual Clinical Encounters

Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

Hospital-to-Home Transitional Care Interventions (H2H-TCI) Children/Youth With Special Health Care Needs (CYSHCN)

Multicenter Study to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Single Tooth Restorations

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Investigating Incidental Pulmonary Nodules in Underserved Communities

Aiming to Improve Readmissions Through InteGrated Hospital Transitions

Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

Genetic Evaluation for Medication Selection (GEMS) Study

Exploratory Study to Evaluate 2 Acupuncture Methods for the Treatment of Headaches Associated With TBI

Improving Asthma Outcomes in an Urban Pediatric Population

A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers

Immunophenotyping Assessment in a COVID-19 Cohort

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Designing Care Management for Hospice Transitions for Persons Living With Advanced Dementia

Hospital for Special Surgery Knee Arthroplasty Cohort

Relationships Between Vitamin D and Orthopedic Trauma

Addressing Sleep in Adolescents Post-Concussion ("ASAP Study")

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)

BETTER (Brain Injury Education, Training, and Therapy to Enhance Recovery)